ImCheck Therapeutics is designing and developing a new generation of butyrophilin-targeting immunotherapy antibodies, with the goal of achieving superior therapeutic efficacy compared to first-generation immune checkpoint inhibitors. The Company's most advanced program, ICT01, is about to enter Phase 2a monotherapy for solid tumors and hematologic cancers, as well as in combination with low-dose anti-PD1 and IL-2 drugs.

ImCheck optimizes its development pipeline by generating monoclonal antibodies (mAbs) for each member of the BTN(L) superfamily, to activate or inhibit different subsets of immune cells. This approach aims to treat pathologies in immuno-oncology (IO), as well as in infectious and autoimmune diseases (AID).